| Original language | English (US) |
|---|---|
| Pages (from-to) | E379-E383 |
| Journal | American journal of hematology |
| Volume | 96 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2021 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American journal of hematology, Vol. 96, No. 10, 01.10.2021, p. E379-E383.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia
T2 - A post hoc analysis from the phase 3 TOWER study
AU - Jabbour, Elias
AU - Patel, Keyur
AU - Jain, Nitin
AU - Duose, Dzifa
AU - Luthra, Rajyalakshmi
AU - Short, Nicholas J.
AU - Zugmaier, Gerhard
AU - San Lucas, Anthony
AU - Velasco, Kelly
AU - Tran, Qui
AU - Zaman, Faraz
AU - Konopleva, Marina
AU - Kantarjian, Hagop
N1 - Funding Information: Elias Jabbour receives research grants from Amgen, Abbvie, Spectrum, BMS, Takeda, Pfizer, Adaptive, and Genentech. Keyur Patel, Rajyalakshmi Luthra, Anthony San Lucas have nothing to disclose. Dr Dzifa Duose receives honorarium for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Chrysallis Biomedical Advisors. Nicholas J. Short receives research grants from Takeda Oncology and Astellas; consulting fees from Takeda Oncology, AstraZeneca, Amgen, NGMBio, and Novartis; honorarium for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Amgen. Nitin Jain receives research grants from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, Servier, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Incyte, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics and payment or honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, Cellectis, TG Therapeutics, and ADC Therapeutics. Gerhard Zugmaier is an inventor or co‐inventor of patent applications/patents belonging to the families of international patent applications published as WO2010/052014, WO2010/052013, WO2011/051307, WO2012/062596, and WO2015/181683. Funding Information: The authors want to acknowledge contributions by Jessica (Chieh) Lan and Ronald Abraham for performing targeted Ph‐like ALL Fusion testing and the ATGC core facility for performing RNA‐seq testing. The authors received medical writing and editing support from Advait Joshi, PhD, of Cactus Life Sciences (part of Cactus Communications), which was supported by Amgen Inc. The study was funded by Amgen Inc. The ATGC core is supported by CA016672(ATGC) and NIH 1S10OD024977‐01 grants. Funding Information: Hagop Kantarjian receives research grants from Amgen, Ascentage, BMS, Daiichi‐Sankyo, Immunogen, Jazz, Pfizer, and Sanofi and honoraria from AbbVie, Actinium, Adaptive Biotechnologies, Amgen, Aptitude Health, BioAscend, Daiichi‐Sankyo, Delta Fly, Janssen Global, Novartis, Oxford Biomedical, Pfizer, and Takeda Oncology.
PY - 2021/10/1
Y1 - 2021/10/1
UR - http://www.scopus.com/inward/record.url?scp=85109168705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109168705&partnerID=8YFLogxK
U2 - 10.1002/ajh.26281
DO - 10.1002/ajh.26281
M3 - Letter
C2 - 34161631
AN - SCOPUS:85109168705
SN - 0361-8609
VL - 96
SP - E379-E383
JO - American journal of hematology
JF - American journal of hematology
IS - 10
ER -